Medicine containing pyrimidine derivative

Details Medicine containing pyrimidine derivative Medicine containing pyrimidine derivative

2002-07-11

2008-09-16

Marschel, Ardin (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S247000

Reexamination Certificate

active

07425559

ABSTRACT:
A medicine for central diseases which contains as the active ingredient either a compound represented by the general formula (I): (I) (wherein R1represents hydrogen or C1-6alkyl; R2represents C1-6alkyl, etc.; A represents carbon, etc.; D represents C1-6alkylene, etc.; E represents carbon, etc.; and Arom represents aryl, etc.) or a pharmacologically acceptable salt of the compound.

REFERENCES:
patent: 4007189 (1977-02-01), Sato et al.
patent: 6245769 (2001-06-01), Arvanitis et al.
patent: 0 347 252 (1989-12-01), None
patent: 0 369 145 (1990-05-01), None
patent: 0 945 442 (1999-09-01), None
patent: 0 945 443 (1999-09-01), None
patent: 1 238 979 (2002-09-01), None
patent: 1 245 567 (2002-10-01), None
patent: 1 266 649 (2002-12-01), None
patent: 51-141896 (1976-12-01), None
patent: 52 116497 (1977-09-01), None
patent: 52-116497 (1977-09-01), None
patent: 53 53697 (1978-05-01), None
patent: 53053698 (1978-05-01), None
patent: 53 68800 (1978-06-01), None
patent: 56 49385 (1981-05-01), None
patent: 56 49391 (1981-05-01), None
patent: 57 35593 (1982-02-01), None
patent: 2-76880 (1990-03-01), None
patent: 10 120683 (1998-05-01), None
patent: WO 83/02944 (1983-09-01), None
patent: WO 98/33799 (1998-08-01), None
patent: WO 00/40561 (2000-07-01), None
patent: WO 01/42247 (2001-06-01), None
patent: WO 02/053526 (2002-07-01), None
patent: WO 02/058697 (2002-08-01), None
Scatena R., et al. “An update on pharmacological approaches to neurodegenerative diseases,” Expert Opin. Investig. Drugs 2007 16(1):59-72.
Rogers J., et al., “Neuroinflammation in Alzheimer's Disease and Parkinson's Disease: are microglia pathogenic in either disorder?” Aug. 2007 Int. Review of Neurobiology vol. 82: abstract only.
Suh, Myung Eun, et al; “Novel Synthesis of 8-tert-Butyl-6,7-Dihydro-5-Methyl-8H-Pyrrolo [3.2-3]-s-Triazolo-[1,5-a] Pyrimidine (Bumepidil), a New Cardiovascular Agent”;College of Pharmacy, Ewha Women's University; 31(5); pp. 338-342 (1987).
Motomura, S., et al; “Characterization of Cardiovascular Actions of CS-611, a New Coronary Dilator, in the Dog”;Arzneimittel-Forschung, Drug Research; 31(8); pp. 1238-1244 (1981).
Kumakura, S., et al; “Cardiovascular Pharmacology of Bumepidil, a New Synthetic Vasoactive Compound for Coronary Circulation”;Arzneimittel-Forschung, Drug Research; 31(5); pp 785-790 (1981).
Yasunobu, S., et al; “Studies on Cardiovascular Agents. 6. Synthesis and Coronary Vasodilating and Antihypertensive Activities of 1,2,4-triazolo[1,5-a]Pyrimidines Fused to Heterocyclic Systems”;Journal of Medicinal Chemistry; 23(8), pp. 927-937 (1980).
Ito, K., et al; “Effects of CS-611 on the Electrophysiological Properties of Canine Cardiac Tissues”;Archives Internationales de Pharmacodynamie et de Therapie; 244(1); pp. 73-85 (1980).
Ebihara, A., et al; “Pharmacokinetics and Pharmacodynamics of the Vasodilator CS-611 in Humans”; 10(1); pp. 89-90 (1979).
Nadhim Bayatti et al; “The neuroprotective actions of corticotrophin releasing hormone” Ageing Research Review, 4 (2005) 258-270.
Domenico Marco Bonifatiet al; “Role of complement in neurodegeneration and neuroinflammation” Molecular Immunology , 44 (5) 999-1010, 2007 (EPUB May 15th, 2006).
Donald R Gehlert et al; “3-(4-Chloro-2-Morpholin-4-ylThiazol-5-yl)-8-(1-Ethylpropyl)-2,6-Dimethyl-Imidazo[1,2-b]Pyridazine:A Novel Brain-Penetrant, Orally Available Corticotropin-releasing Factor Receptor 1 Antagonist with Efficacy in Animals Models of Alcoholism” The Journal of Neuroscience, Mar. 7, 2007, 27(10) 2718-2726.
Alexander Gerhard et al; “In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease”, Neurobiology of Disease 21 (2006) 404-412.
Paul J Gilligan et al “Corticotropin-releasing factor receptor antagonists”, Expert Opin. Ther.Patents (2006) 16(7): 913-924.
E Hansson “Could chronic pain and spread of pain sensation be induced and matained by glial activation?”, Acta Physiol 2006, 187, 321-327.
Shawn Hayley et a; “Multiple Mechanisms of Cytokine Action in Neurodegenerative and Psychiatric States: Neurochemical and Molecular Substrates”., Current Pharmacejutical Designs 2004, 11, 947-962.
Katia Karalis et al; “Autocrine or Paracrine Inflammatory Actions of Corticotropin-Releasing Hormone in Vivo”, Science. vol. 254, Issue 5040, 421-423.
Yasuomi Ouchi et al; “Microglial Activation and Dopamine Terminal Loss in Early Parkinson's Disease”, Ann Neurol 2005; 57; 168-175.
Emma Schofield et al; “Severity of gliosis in Pick's disease and frontotemporal lobar degeneration: tau-positive glia differentiate these disorders”,Brain (2003), 126, 827-840.
Myung Eun Suh et al “8-tert-Butyl-6,7-Dihydro-5-Methyl-8H-Pyrrolo [3,2-e]-s-Triazolo-[1.5-a] Pyrimidine (Bumepidil)”, Yakhak Hoeji Vo. 31, No. 5 338-342 (1987).
Peter Teismann et al “Cellular pathology of Parkinson's disease: astrocytes, microglia and inflammation”, Cell Tissue Res (2004) 318, 149-161.
Theoharis C. Theoharides et al; “Corticotropin-Releasing Hormone Induces Skin Mast Cell Degranulation and Increased Vascular Permeability, A possible explanation for its proinflammatory effects”, Endocrinology 139; 403-413, 1998.
Shigeko Uryu et al: “β-Amyloid-specific upregulation of stearoyl coenzyme A desaturase-1 in macrophages”, Biochemical and Biophysical Research Communications 303 (2003) 302-305.
P J Whitehouse et al; “Reductions in corticotrophin releasing factor-like immunoreactivity in cerebral cortex in Alzheimer's disease, Parkinson's disease, and progressive supranuclear palsy”, Neurology 1987: 37: 905-909.
Brandy Wilkinson et al; “Fibrillar Beta-Amyloid stimulated intracellular signaling cascades require vav for induction of respiratory burst and phagocytosis in monocytes and microglia”, J. Biol. Chem. Jul. 2006, 281: 20842-20850 (E-Pub 25thMay 2006).
Marcin Wojtera et al; “Microglial cells in neurodegenerative disorders”; Folia Neuropathol 2005; 43 (4) 311-321.
Katia Karalis et al; “Autocrine or Paracrine Inflammatory Actions of Corticotropin-Releasing Hormone in Vivo”, Science. vol. 254, Issue 5040, 421-423 , Oct. 1991.

Affiliated with

Also associated with

Rating

Medicine containing pyrimidine derivative does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Medicine containing pyrimidine derivative, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Medicine containing pyrimidine derivative will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3990135